Before the General Meeting of Shareholders, Imexpharm announced good news for the first quarter of 2025: Net revenue reached 594 billion VND

Outstanding financial results

Imexpharm recorded gross revenue of VND672 billion, up 23% year-on-year, completing 23% of the annual revenue plan submitted to the General Meeting of Shareholders. Net revenue reached VND594 billion, up 21% year-on-year, thanks to outstanding performance from both OTC and ETC channels, along with a product portfolio that meets rapidly changing market demand. In addition to the steady growth of antibiotics, cough medicine, contributing 11% of total revenue, recorded a growth of 42% year-on-year, amid the outbreak of respiratory diseases in the first months of the year.

OTC channel revenue recovered impressively, increasing by 25% over the same period, with the Northern region alone increasing sharply by 69%, contributing 12% to total OTC channel revenue. Business results in the Northern region exceeded expectations in the first quarter, with the number of customers transacting increasing by 30% over the same period.

The ETC channel recorded a growth of 27% over the same period, thanks to efforts to strengthen cooperation with the hospital network and a high-quality product portfolio that meets market demand. In the first quarter, Imexpharm also began to execute national bids, participating in providing stable quality and highly effective drugs to medical facilities nationwide.

Gross profit increased sharply by 30%, far exceeding revenue growth, thanks to effective control of cost of goods sold, which increased by only 16% year-on-year. Production activities were boosted at all EU-GMP-certified factories, with IMP4 increasing output by up to 126% year-on-year. Gross profit margin increased to 40%, the highest level since the first quarter of 2024. Profit before tax (PBT) reached VND95 billion, up 23% year-on-year. thanks to a breakthrough in revenue and effective control of production costs; EBITDA reached VND126 billion, up 16% year-on-year, with EBITDA margin reaching 21%.

Outstanding business activities

Ms. Tran Anh Tu, Secretary of the City Youth Union, Da Lat City, spoke at the ceremony of presenting 500 trees from Imexpharm to the City Youth Union of Da Lat City. Photo: Imexpharm

On March 14, 2025, Imexpharm donated trees to the Da Lat City Youth Union, responding to the goal of planting 50 million trees of Lam Dong province in the period of 2021 - 2025. This is part of the Sales & Marketing Congress 2025 with the theme "Pioneering the way", continuing the journey for the community that Imexpharm has persistently carried out.

In addition, Imexpharm is honored to be announced in the Top 10 Green ESG Enterprises in Vietnam in the Pharmaceutical - Medical Equipment Industry (ESG10 - 2025), organized by Viet Research in collaboration with the Finance - Investment Newspaper (Ministry of Finance). The award aims to recognize enterprises with outstanding commitment and implementation of ESG criteria, according to international standards, while contributing to building a comprehensive ESG database for Vietnam.

In the last two weeks of March 2025, Imexpharm continued to affirm its pioneering role and sustainable commitment in its nearly 50-year journey accompanying the healthcare sector and the community, when it became a sponsor for two large-scale medical science events: the 41st Annual Otolaryngology Scientific Conference (March 21-23 in Da Nang) and the Scientific Conference celebrating the 20th anniversary of Thien Hanh General Hospital (March 27 in Buon Ma Thuot).

On April 10-11, 2025, Imexpharm organized an online seminar with the topic: "Strategy for using antibiotics in the treatment of respiratory infections in the era of multidrug resistance". The event brought together leading experts in the fields of pharmacy and respiratory medicine, and also granted CPE certificates to the participating pharmacists. Imexpharm is expected to continue its scientific activities with a seminar taking place at the end of April.

The Company has released its 2024 Annual Report, highlighting its achievements over the past year and its direction for the coming period. In the first 3 months of 2025, the Company launched 9 new products with 133 ongoing R&D projects.

Market outlook

Vietnam’s pharmaceutical market is forecast to grow steadily due to an aging population and increased government investment in the healthcare sector. New generation antibiotics produced according to EU-GMP standards are maintaining strong growth momentum. Urbanization trends and high life expectancy will boost demand for digestive, cardiovascular, diabetes, and obesity drugs in the next 10 years. Favorable policies and demand for high-tech drugs open up great opportunities for domestic pharmaceutical enterprises to innovate.

Employees working at the Imexpharm factory. Photo: Imexpharm.

Sharing about this result, People's Physician, Pharmacist Tran Thi Dao, General Director of Imexpharm, said: “Imexpharm started 2025 with impressive first quarter results, achieving net revenue and pre-tax profit growth of 21% and 23%, gross profit margin improved to 40% as cost of goods sold was well controlled.

This growth momentum is reinforced by the breakthrough in the Northern market, reflecting the effectiveness of restructuring and market development activities that have been carefully prepared throughout 2024. Based on this solid foundation, we prioritize promoting the drug segment with advanced dosage forms and production technology, high value and outstanding treatment effectiveness. With a pioneering position, I believe that this strategic orientation will bring sustainable efficiency in production and business activities and enhance the value of Imexpharm in the long term."

Imexpharm will share its strategic vision for the coming period at the Annual General Meeting of Shareholders, held on April 25, 2025, with a focus on market development, innovation and sustainable value creation.

Source: https://baodautu.vn/truoc-them-dhdcd-imexpharm-bao-tin-vui-quy-i2025-doanh-thu-thuan-dat-594-ty-dong-d269271.html